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Reply to the Editor: 
My colleagues and I thank Masaoka and his associates for 
their letter and discussion. The authors point out one of the 
problems in dealing with tumors of the thymus: a variety of 
pathologic classifications have been devised, and the recent 
introduction of new classifications has caused a significant 
amount of confusion. A single classification of thymic tumors 
is greatly needed. 
We agree that well-differentiated thymic carcinoma is dif-
ferent from type II malignant thymoma. The point of our arti-
cle was that both of these malignant diseases can be aggres-
sive. We found that the tumors with the worst prognosis were 
those invading the innominate vein. Regardless of the patho-
logic diagnosis, fewer than 50% of patients treated for such 
tumors with complete resections will be disease-free at 5 
years, despite surviving. As Fig 1 in our original article 
demonstrates, even stage I and II thymic carcinoma will have 
a propensity to recur. In 10 years, 90% of thymic carcinomas 
of either type will recur, despite complete resection. 
We therefore concluded that either of these entities requires 
a much more aggressive management and might benefit from 
multimodality therapy. 
Robert J. Ginsberg, MD 
Department of Thoracic Surgery 
Memorial Sloan Kettering Cancer Center 
1275 York Ave 
New York City, NY 10021 
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Controlled cardiac reoxygenation in adults with 
ischemic heart disease 
To the Editor: 
We read with fascination the report by Kai Ihnken and 
associates I printed in the August 1998 issue of the Journal, in 
which standard, hyperoxic arterial POzs were compared with 
"normoxic" POzs during cardiopulmonary bypass (CPB) and 
found to cause measurable biochemical evidence of injury at 
the cellular level. We would like to ask several questions and 
to comment. Our questions relate to the initiation of anesthe-
sia in the patients who were subjected to normoxic CPB. The 
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common practice is for anesthesiologists to intubate and 
hyperoxygenate every patient, both during and after induc-
tion. Is this the way the patients in this group were handled? 
If so, could they not also have had an initial "reoxygenation" 
injury occurring at the time of anesthesia induction, if the POl 
of arterial blood was allowed to rise to extremely high levels 
before the initiation of CPB? Might the biochemical evidence 
of injury in the group subjected to hyperoxic bypass have 
been even more pronounced, by comparison, had prebypass 
POzs been controlled to physiologic levels upon intubation 
and induction of anesthesia in the other group of patients? 
Furthermore, might all of us be unintentionally contributing 
to injury of the heart in other clinical situations as well? 
We are in full agreement that the way in which oxygen is 
administered to adult patients with ischemic heart disease 
needs to be rethought. From our reading, it appears that this 
work represents a prolog to the introduction of "controlled 
cardiac reoxygenation," a concept borrowed from congenital 
heart surgery and used successfully in cyanotic children,z,3 
into another clinical area in which it may be applicable. This 
study suggests that, even in the adult patient with coronary 
heart disease and a "normoxic heart," considerable and cer-
tainly measurable cellular injury is occurring because of 
some of the known, toxic effects of high levels of molecular 
oxygen introduced abruptly into the coronary circulation. 
We would like to share our experience with the use of a 
strategy of controlled cardiac reoxygenation with 6 consecu-
tive patients taken to the operating room in the setting of 
advanced, evolving myocardial infarction. All were referred 
for emergency revascularization because catheter-based ther-
apies either were judged to be not feasible by the cardiologist 
or had failed to successfully interrupt the unstable syndrome. 
Half were in cardiogenic shock (pulmonary capillary wedge 
pressure> 18 mm Hg, cardiac index < 2.0 Llmin per square 
meter) at the time of entry to the operating room. All had 
multivessel coronary disease, profound diffuse myocardial 
contractile dysfunction (mean preoperative left ventricular 
ejection fraction was 28%), and had been having active 
symptoms for greater than 6 hours. Coexistent medical con-
ditions were what would be expected for such a patient pop-
ulation with a mean age of nearly 68 years. An average of 4 
bypass grafts was accomplished. In all 6 patients, deoxy-
genated blood cardioplegic solution was administered for ini-
tial warm induction and the POz of the reperfusate (initially 
35-45 mm Hg) was gradually raised over 20 minutes by alter-
ing the FIOZ of the membrane oxygenator and by changing the 
admixture of venous and arterial blood in the cardioplegia 
circuit. The pH of the initial cardioplegic solution, although 
from the venous side of the bypass circuit, was controlled in 
the normal range by adding bicarbonate or tromethamine as 
needed. The operations were completed with the use of inter-
mittent doses of cold (4°C) hyperoxygenated blood cardio-
plegic solution and a "hot shot" at the end of the crossclamp 
interval. In this group of patients, whom we expected to do 
relatively poorly on the basis of previous experience, we have 
had no deaths and the mean time to discharge from the hos-
pital was 8 days. The mean time to extubation for the group 
